Clinical Trials Arena July 25, 2024
Newpath Partners spearheaded the funding round, which saw contributions from other new investors.
Autobahn Therapeutics has secured $100 in an oversubscribed Series C financing round for the commencement of two Phase II clinical trials of ABX-002 to treat major depressive disorder (MDD) and bipolar disorder depression.
Newpath Partners spearheaded the funding round, which saw contributions from new investors, which included Monograph Capital, Canaan Partners and Insight Partners.
All of Autobahn’s existing investors also participated, among them are founding investors ARCH Venture Partners and Blue Owl Healthcare Opportunities, BVF Partners, Samsara BioCapital, Invus, Biogen, Pfizer Ventures, Bristol Myers Squibb, Section 32, GT Healthcare Capital Partners and Alexandria Venture Investments.
A selective thyroid hormone beta receptor (TRβ) agonist, ABX-002 has shown promise...
Today's Sponsors
Today's Sponsor